Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
Cancer Epidemiol Biomarkers Prev. 2021 Oct;30(10):1974-1976. doi: 10.1158/1055-9965.EPI-21-0323. Epub 2021 Jul 21.
Antibiotics may increase colorectal neoplasia risk by modifying the gut microbiome. It is unknown whether use is associated with the risk of new colorectal adenomas among individuals with prior adenomas.
We performed a secondary analysis of four randomized clinical trials for the chemoprevention of colorectal adenomas. Participants self-reported all currently used prescription drugs shortly after an initial colorectal adenoma diagnosis and two or three times a year thereafter over 3 to 5 years of follow-up. We estimated adjusted risk ratios (RR) with 95% confidence intervals (CI) for incident adenomas, analyzing the four trials together.
Cumulatively, the four trials enrolled 5,174 participants (3,491 men and 1,683 women), of whom 4,769 (92%) completed ≥1 follow-up colonoscopy. A total of 763 (15%) participants reported using oral antibiotics on ≥2 occasions. Overall, 39% of those using oral antibiotics at least twice developed new colorectal adenomas compared with 40% of those with no use or a single report of use (RR, 0.99; 95% CI, 0.90-1.10). No statistically significant associations were found in study-specific analyses, and results were similar for high- and low-risk adenoma findings, antibiotic class, anatomic location of adenomas, and analyses excluding those with interim colorectal exams.
Oral antibiotic use during colonoscopic surveillance after an initial adenoma diagnosis was not associated with risk of these polyps.
Any changes to the gut microbiome as a consequence of oral antibiotic use during surveillance may not affect the development of metachronous colorectal adenomas.
抗生素可能通过改变肠道微生物群来增加结直肠肿瘤的发生风险。目前尚不清楚在有先前腺瘤的个体中,抗生素的使用是否与新发结直肠腺瘤的风险相关。
我们对四项用于结直肠腺瘤化学预防的随机临床试验进行了二次分析。参与者在首次结直肠腺瘤诊断后不久以及此后的 3 至 5 年随访期间每年两次或三次自我报告所有当前使用的处方药。我们通过对四项试验进行联合分析,估计了新发腺瘤的校正风险比(RR)及其 95%置信区间(CI)。
四项试验共纳入 5174 名参与者(3491 名男性和 1683 名女性),其中 4769 名(92%)完成了至少 1 次随访结肠镜检查。共有 763 名(15%)参与者报告至少两次使用口服抗生素。总的来说,与未使用或仅报告使用一次的参与者相比,至少两次使用口服抗生素的参与者新发结直肠腺瘤的比例为 39%,而未使用或仅报告使用一次的参与者为 40%(RR,0.99;95%CI,0.90-1.10)。在研究特异性分析中未发现统计学显著相关性,且对于高危和低危腺瘤发现、抗生素类别、腺瘤的解剖位置以及排除中间结肠镜检查的分析,结果均相似。
在首次腺瘤诊断后的结肠镜监测期间使用口服抗生素与这些息肉的风险无关。
在监测期间使用口服抗生素对肠道微生物群的任何改变可能不会影响结直肠腺瘤的发生。